La d A 47 year old man with a diagnosis of acute myeloid leukemia with a blood type O negative blood group presents to the transplant clinic to discuss proceeding with an allogeneic stem cell transplant. Which of the following would be an optimal donor?

Correct Answer: D. His HHLA identical 50-year-old brother who is otherwise healthy and is blood type O+

In allogeneic stem cell transplantation (ASCT), the optimal donor is an HLA-identical sibling, which provides the best balance of engraftment, survival, and minimal graft-versus-host disease (GVHD). The patient's HLA-identical brother (Option D) is the gold standard because: (1) HLA matching reduces GVHD risk dramatically—identical siblings have 25% chance of HLA match, making them superior to unrelated donors; (2) sibling donors have established immunological tolerance and lower rejection rates; (3) blood type incompatibility (O+ donor to O− recipient) is not a contraindication in ASCT—the donor's blood type is replaced by the recipient's immune system post-transplant, and minor ABO incompatibility is manageable with plasma exchange if needed; (4) the donor's age (50 years) is acceptable as long as he is healthy with normal organ function (per EBMT/CIBMTR criteria). In Indian transplant centers following NCCN/EBMT guidelines, HLA-identical siblings remain the preferred choice for ASCT when available, with superior 5-year survival compared to unrelated donors.

Why the other options are wrong

A. An HLA identical matched unrelated donor who is blood type O− — While HLA-matched unrelated donors are acceptable alternatives, they are inferior to HLA-identical siblings due to higher GVHD incidence (20–30% grade III–IV vs. 5–10% in siblings), higher transplant-related mortality, and lower overall survival. Unrelated donors are used only when no sibling match exists. The blood type match here is irrelevant—the real disadvantage is the unrelated status. B. Umbilical cord transplant — Cord blood transplants have delayed engraftment (60–90 days vs. 14–21 days for bone marrow), higher graft failure rates (5–10%), and are reserved for pediatric patients or when no adult donor is available. In a 47-year-old with AML, an adult HLA-identical sibling is far superior. Cord blood is not optimal for this patient. C. His identical twin brother — Identical twins are syngeneic donors (100% HLA match) and theoretically ideal, but are extremely rare (1 in 250 births). More critically, syngeneic transplants lack the graft-versus-leukemia (GVL) effect—the donor immune system cannot recognize and eliminate residual leukemic cells, leading to higher relapse rates. HLA-identical siblings retain some GVL benefit while maintaining low GVHD.

High-Yield Facts

Mnemonics

ASCT Donor Hierarchy (Best to Worst) HLA-ID Sibling > HLA-ID Unrelated > Haploidentical > Cord Blood > Syngeneic (for relapse risk). Remember: Siblings beat unrelated because of lower GVHD; syngeneic is worst for AML because no GVL effect. Why Syngeneic is Bad in Leukemia No GVL = Relapse Risk. Identical twins = zero GVHD but also zero graft-versus-leukemia immunity → donor cells don't attack cancer → higher relapse.

NBE Trap

NBE pairs "identical twin" with "perfect match" to lure students into thinking syngeneic transplants are optimal. The trap: students forget that GVL effect (beneficial graft-versus-leukemia immunity) is lost in syngeneic transplants, making them inferior for hematologic malignancies despite zero GVHD risk.

Clinical Pearl

In Indian transplant centers (AIIMS, Tata Memorial), HLA-identical siblings are actively sought first because they offer the best long-term AML-free survival. When unavailable, unrelated donor registries (BMDRI, NMDRI) are searched, but these take 3–6 months. The patient's O+ brother is immediately available and HLA-matched—a rare clinical gift that should not be missed.

_Reference: Harrison Ch. 109 (Hematopoietic Stem Cell Transplantation); EBMT/CIBMTR ASCT guidelines; Robbins Ch. 4 (Immunology of transplantation)_